Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (172)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Etentamig	Bispecific T-Cell Engager, BCMA x CD3	Hematologic (Multiple Myeloma)
Molecule Etentamig Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, BCMA x CD3
Evorpacept	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Evorpacept Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Forimtamig	Bispecific T-Cell Engager, GPRC5D x CD3	Hematologic (Multiple Myeloma)
Molecule Forimtamig Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, GPRC5D x CD3
Golcadomide	Cereblon E3 Ligase Modulator (CELMoD)	Hematologic (Lymphoma)
Molecule Golcadomide Therapeutic Category Immunomodulatory Agent Oncology Type Hematologic (Lymphoma) Drug Class / Mechanism Cereblon E3 Ligase Modulator (CELMoD)
Guadecitabine	Hypomethylating / Investigational Agent	Hematologic (MDS/AML)
Molecule Guadecitabine Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (MDS/AML) Drug Class / Mechanism Hypomethylating / Investigational Agent
Ianalumab	Targeted Protein Degrader	Hematologic
Molecule Ianalumab Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
IBI322 (CD47/PD-L1)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule IBI322 (CD47/PD-L1) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Lemzoparlimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Letaplimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Magrolimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Magrolimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Nemtabrutinib	Reversible (Non-Covalent) BTK Inhibitor	Hematologic (Lymphoma/CLL)
Molecule Nemtabrutinib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Reversible (Non-Covalent) BTK Inhibitor
NX-2127 (BTK Degrader)	Targeted Protein Degrader	Hematologic
Molecule NX-2127 (BTK Degrader) Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader

Etentamig Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, BCMA x CD3
Evorpacept Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Forimtamig Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, GPRC5D x CD3
Golcadomide Immunomodulatory Agent
Therapeutic Category Immunomodulatory Agent Oncology Type Hematologic (Lymphoma) Drug Class / Mechanism Cereblon E3 Ligase Modulator (CELMoD)
Guadecitabine Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (MDS/AML) Drug Class / Mechanism Hypomethylating / Investigational Agent
Ianalumab Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader
IBI322 (CD47/PD-L1) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Magrolimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Nemtabrutinib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Reversible (Non-Covalent) BTK Inhibitor
NX-2127 (BTK Degrader) Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism Targeted Protein Degrader

‹ 1 … 12 13 14 15 ›

Product Range

Company

Global Network

Products

All Products (172)

Etentamig

Evorpacept

Forimtamig

Golcadomide

Guadecitabine

Ianalumab

IBI322 (CD47/PD-L1)

Lemzoparlimab

Letaplimab

Magrolimab

Nemtabrutinib

NX-2127 (BTK Degrader)

Etentamig

Evorpacept

Forimtamig

Golcadomide

Guadecitabine

Ianalumab

IBI322 (CD47/PD-L1)

Lemzoparlimab

Letaplimab

Magrolimab

Nemtabrutinib

NX-2127 (BTK Degrader)